What is 5-Amino-1MQ? What it does, benefits and what the evidence shows

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of an enzyme called nicotinamide N-methyltransferase, or NNMT. It is not a peptide, even though it is sold on the same grey market pages as peptides and gets discussed in the same fat-loss threads. Its reputation rests on a small set of mouse studies in which NNMT inhibitors reduced body weight and fat mass in obese animals. We found no published human study of it, and no registered human trial.

What 5-Amino-1MQ is and how it works

Peptides are short chains of amino acids. 5-Amino-1MQ is a different kind of molecule altogether: a small, positively charged quinoline-derived compound that was designed as a drug-discovery tool. It was built to block NNMT, an enzyme that uses up nicotinamide (a form of vitamin B3) and a methyl-donor molecule called SAM. The idea is that if you block NNMT in fat cells, cells keep more NAD+ and SAM, and shift toward burning energy rather than storing it.

The main paper behind the compound is a 2018 study (Neelakantan et al., Biochemical Pharmacology). It tested a series of methylquinolinium compounds and reported that the amine-substituted versions crossed cell membranes well and did not inhibit related methyltransferases or the enzymes of the NAD+ salvage pathway. In cultured fat cells, the inhibitors lowered the NNMT reaction product, raised intracellular NAD+ and SAM, and suppressed fat accumulation (Neelakantan et al., 2018).

If the NAD+ connection sounds familiar, it is the same molecule we cover in our NAD+ guide. The difference is that 5-Amino-1MQ does not supply NAD+; the hypothesis is that it changes how cells handle the raw materials for it, and that hypothesis has only been tested in cells and mice.

What people use it for

What the research actually shows

Fat loss in obese mice

In the 2018 study, obese male mice fed a high-fat diet were treated with 5-Amino-1MQ for 11 days. They lost about 5.1% of their starting body weight while controls gained about 1.4%, had roughly 35% less mass in the epididymal fat pad, had fat cells more than 30% smaller, and had total cholesterol about 30% lower than controls. Food intake did not differ between the groups, which the authors took to mean the effect was not just appetite suppression. The paper reports no observable adverse effects in the animals (Neelakantan et al., 2018). Those are results from one short course in one mouse model, in one lab.

A 2021 follow-up from overlapping authors combined an NNMT inhibitor with a switch to a lower-calorie diet in obese mice. The combination produced faster and more durable weight and fat loss than the diet change alone, and brought body composition back toward that of lean mice (Sampson et al., Scientific Reports, 2021).

A 2024 study tested 5-Amino-1MQ itself across several amounts in male obese mice. It found dose-dependent limits on weight and fat gain, better glucose tolerance and insulin sensitivity, and less fat in the liver (Babula et al., 2024). Worth knowing: one author founded Ridgeline Therapeutics, a company developing NNMT inhibitors, and other authors work or worked there, which the paper discloses. That does not make the results wrong, but the mouse data comes largely from the people who built the compound.

What that does and doesn't tell you about people

Mouse results often fail to carry over to people, and nothing in these papers tells you what the compound does in a human body: how much is absorbed, how long it lasts, what it does to other tissues, or whether the fat-loss effect exists at all. A 2024 review of NNMT as a drug target says outright that clinical trials focused on NNMT have not been documented (Sun et al., Frontiers in Pharmacology, 2024). We also searched ClinicalTrials.gov on September 29, 2026 for 5-Amino-1MQ and for its chemical name and found no registered studies (ClinicalTrials.gov). A 2026 review says newer NNMT inhibitors were developed to fix the limited target engagement, poor bioavailability and unknown safety profiles that held earlier ones back, which is another way of saying the field is still working toward clinical translation (Puleo et al., Trends in Pharmacological Sciences, 2026).

Muscle, energy and anti-aging claims

Marketing often adds muscle preservation, energy or longevity to the list. The 2021 diet study reported a higher lean-mass-to-body-weight ratio in treated mice, which is a body composition ratio in a diet-restricted animal, not a demonstrated muscle-building effect. We found no human data supporting any of these claims, so they are Anecdotal in the table above.

Side effects and risks

There is no human safety data. In mice, the 2018 paper reported no observable adverse effects, but that is a short study in animals that were watched for obvious problems, not a toxicology program.

One specific flag comes from the 2024 paper. When the authors screened 5-Amino-1MQ against a broad panel of receptors, enzymes and transporters, it showed no significant activity against everything tested except a 67.4% inhibition of monoamine oxidase-A (MAO-A). The authors say it is possible that some of the glucose-tolerance improvement was partly mediated by that off-target activity (Babula et al., 2024). The paper does not tell us what that would mean in a person, but it is a reason the compound's behavior in humans is unpredictable, and it is the kind of thing a formal safety program would investigate before any human use.

Beyond that, the honest list of unknowns is long: how the compound is absorbed and cleared in people, what long-term NNMT inhibition does to methylation-dependent processes, interactions with medications, and effects in anyone with existing health conditions. Grey-market risks sit on top of that, because a vial sold as 5-Amino-1MQ has no manufacturing standard you can point to; the section below shows what independent lab reports find.

What the lab tests show

As of September 29, 2026, our database includes 4 vials of 5-Amino-1MQ, all from a single vendor, drawn from 2 lab reports dated August and September 2025. That is a very small sample from one source, so it says something about those vials and very little about the compound in general or about any vendor's typical quality.

All 4 vials measured 99% pure or higher, with a median of 99.15%. On dose against label, the median was 4.8% over. Two vials landed within 5% of label and 3 within 10%, while 1 vial measured about 32% over label. None met our failure definition (empty, under 95% pure, more than 20% under label, or more than 50% over), so failed vials are 0 of 4. The 32% overfill would count as a warning sign on a bigger dataset, but it is below the 50% overfill cutoff we use.

With every result coming from one vendor, the table below may be empty. A vendor needs five or more lab reports before it is ranked, and here is how the ranked vendors for 5-Amino-1MQ look right now:

Buying smarter

Because our data on this compound is thin, treat any vendor's record as unproven for it. Check the 5-Amino-1MQ results page for the current numbers, and look at how many separate reports and how many separate vendors sit behind them. A clean record from one source is a starting point, not a verdict.

A posted certificate of analysis is worth reading critically: see how to read a peptide COA and fake peptide COAs for the red flags. If you want to know what is in your own vial, how to get a peptide tested walks through independent identity, purity and quantity testing. Because 5-Amino-1MQ is a small molecule rather than a peptide, check with the lab that it can identify it and quantify it against a proper standard before you order.

If your report comes back with a fail, stop using that batch, tell anyone else who bought from the same run, bring the report to the vendor, and submit it to VendorVerify so the next buyer has one more data point. If you have a lab report for this compound, that is exactly the data that gets it a ranking.

For related reading, MOTS-c and AOD-9604 are two other metabolism-focused compounds sold in the same market, with very different evidence behind them.

Database figures are from VendorVerify as of September 29, 2026. This isn't medical advice. 5-Amino-1MQ is sold for research use only and has not been evaluated by FDA for safety or effectiveness in humans.